Rafferty Asset Management LLC Lowers Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Rafferty Asset Management LLC reduced its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 5.0% during the 4th quarter, HoldingsChannel reports. The firm owned 249,173 shares of the biopharmaceutical company’s stock after selling 13,185 shares during the period. Rafferty Asset Management LLC’s holdings in Dynavax Technologies were worth $3,182,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Russell Investments Group Ltd. grew its holdings in Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 2,034 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Dynavax Technologies during the fourth quarter valued at approximately $71,000. Nisa Investment Advisors LLC increased its holdings in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 1,076 shares during the period. Finally, KBC Group NV increased its holdings in Dynavax Technologies by 68.7% during the fourth quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 2,857 shares during the period. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Price Performance

NASDAQ DVAX opened at $9.67 on Monday. Dynavax Technologies Co. has a 12-month low of $9.22 and a 12-month high of $14.63. The firm’s fifty day simple moving average is $11.78 and its two-hundred day simple moving average is $12.51. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.16 billion, a P/E ratio of 53.72 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $68.16 million for the quarter, compared to analysts’ expectations of $70.01 million. Analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on DVAX shares. The Goldman Sachs Group lowered their target price on Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a report on Thursday, April 17th. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. JMP Securities dropped their price objective on Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $24.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.